PRAXIS PRECISION MEDICINES $PRAX
Culper Research • Published November 20, 2025 • Engineered Phase 3 Results Through Statistical Manipulation
CORE INVESTMENT THESIS
Praxis Precision Medicines is a clinical-stage biotech that manipulated Phase 3 trial results through last-minute endpoint changes and questionable statistical methods to manufacture positive data for ulixacaltamide in essential tremor.
After an independent data monitoring committee recommended stopping the trial for futility in March 2025, Praxis continued the study and changed the primary endpoint from 12 weeks to 8 weeks—a modification never approved by the FDA. Following the announcement of these "positive" results, Praxis raised $567 million, despite the drug having been acquired for just $1 million in 2018 after prior owners failed to develop it. Culper Research concludes this represents a materially overvalued company built on engineered clinical data.
COMPANY OVERVIEW
Ulixacaltamide acquired in 2018 for $1M after previous owners failed development—yet now valued at $3B by analysts
Raised in October 2025 immediately after announcing "positive" Phase 3 results with changed endpoints
Sell-side analysts value ulixacaltamide at $3B with 80% probability of success—company's total market cap is $4.5B
Of patients in treatment arm discontinued the trial, yet Praxis attributed "overly optimistic results" to these dropouts
TIMELINE OF ALLEGED MANIPULATION
CULPER'S PRIMARY ALLEGATIONS
- Unapproved Endpoint Change: Praxis made a "last-minute endpoint change" from 12 weeks to 8 weeks that was never approved by the FDA, fundamentally altering the statistical analysis plan to manufacture positive results.
- Misattribution of Dropout Data: Praxis attributed "overly optimistic results" to the 36% of patients in the treatment arm who discontinued the trial, improperly handling missing data to inflate efficacy.
- Misapplied Methodology: The company allegedly implemented statistical methodology incorrectly to create positive results, deviating from standard practices without proper regulatory approval.
- Ignored Futility Finding: Despite an independent data monitoring committee recommending trial stoppage for futility in March 2025, Praxis continued enrollment and changed endpoints to salvage the study.
- Historical Drug Failures: Three other drugs with the same mechanism of action (T-type calcium channel inhibitors) failed in early trials for essential tremor, yet Praxis claims breakthrough results.
- Suspicious Acquisition Price: Ulixacaltamide was acquired for only $1 million in 2018—an extraordinarily low price suggesting previous owners saw no value after failing to develop the drug themselves.
- Opportunistic Capital Raise: Immediately after announcing "positive" results with changed endpoints, Praxis raised $567 million before full data disclosure, potentially taking advantage of inflated stock price.
- Expert Validation: Culper consulted with former Praxis directors, biostatisticians, and four former FDA managers (10-40 years experience each) who corroborated concerns about the trial conduct and data analysis.
KEY PLAYERS
Role in Thesis: Led the company through the controversial Phase 3 trial, defended endpoint changes, and orchestrated the $567M capital raise following "positive" results announcement.
Significance: Committee noted that "underlying assumptions of the statistical model might have influenced the futility finding"—a statement Praxis allegedly exploited to justify continuing the trial.
Key Question: Whether FDA actually approved the last-minute switch from 12-week to 8-week primary endpoint—a critical detail that could invalidate the entire trial.
Findings: Unanimous concern about trial conduct, endpoint changes, data handling, and statistical methodology. Provided expert validation for Culper's short thesis.
Valuation: Analysts estimate ulixacaltamide has 80% probability of success and $3B peak sales potential. Culper argues this optimism is based on manipulated data.
Implication: The fire-sale price suggests sophisticated drug developers saw little promise in the molecule—contrary to Praxis's current $3B+ valuation claims.
MECHANISM COMPARISON: FAILED T-TYPE CALCIUM CHANNEL INHIBITORS
According to Culper Research, three other drugs with the same mechanism of action (T-type calcium channel inhibition) have already failed in early clinical trials for essential tremor:
Mechanism of Action
T-type calcium channel inhibition targeting Cerebello-Thalamo-Cortical (CTC) circuit
Historical Failures
Three prior drugs with identical mechanism failed in early-stage essential tremor trials
Ulixacaltamide Status
Despite identical mechanism and prior failures, Praxis claims "breakthrough" results after endpoint changes
Culper's Conclusion: The pattern of failures for this drug class raises serious questions about ulixacaltamide's genuine efficacy—particularly given the trial was only "rescued" through last-minute endpoint modifications.
Culper Research's Verdict
According to Culper Research, Praxis Precision Medicines ($PRAX) is a materially overvalued clinical-stage biotech that engineered positive Phase 3 results through statistical manipulation. The company allegedly made a last-minute endpoint change from 12 weeks to 8 weeks that was never approved by the FDA, mishandled missing data from the 36% of patients who discontinued treatment, and continued a trial despite a futility recommendation from independent monitors. Ulixacaltamide was acquired for just $1 million in 2018 after previous owners failed to develop it, yet Praxis raised $567 million following the announcement of these questionable results. After consulting with former Praxis directors, biostatisticians, and multiple former FDA managers, Culper Research concludes that the company's current $4.5 billion market capitalization is built on manipulated clinical data.
- ✓ Unapproved last-minute endpoint change (12 weeks → 8 weeks)
- ✓ Ignored independent committee's futility recommendation
- ✓ Mishandled data from 36% patient discontinuation rate
- ✓ Drug acquired for $1M after previous development failures
- ✓ Three similar drugs with same mechanism already failed
- ✓ Raised $567M immediately after questionable results
- ✓ Expert validation from former FDA managers and biostatisticians